GNE myopathy is a distal myopathy that is thought to be caused by a mutation in the GNE gene that encodes an enzyme in the biosynthetic process of aceneuramic acid (typical sialic acid). The investigators will examine the efficacy and safety of aceneuramic acid (SA-ER tablets) 6g daily for 48 weeks in patients with GNE myopathy in a placebo-controlled, double-blind, controlled trial.
GNE myopathy is a distal myopathy that is thought to be caused by a mutation in the GNE gene that encodes an enzyme in the biosynthetic process of aceneuramic acid (typical sialic acid). It is an extremely rare progressive muscle disease, often occurring in the late teens to 30s, usually affecting the distal lower leg, especially the extensor muscles such as the tibialis anterior muscle, first, and weakness in both upper and lower limbs. However, the weakness of the quadriceps femoris is usually gradual. Although there are large individual differences, health management and deterioration of QOL will eventually become a problem, and in severe cases, constant assistance is required in daily life. A double-blind comparative study conducted in Japan provided results suggesting efficacy, but the efficacy could not be confirmed in a large-scale international clinical trial, so this study is decided to be conducted. Oral administration of aceneuramic acid tablets 500 mg (SA-ER tablets) or placebo tablets of the same appearance, 4 tablets at a time, 3 times a day for 48 weeks will be examined for differences in efficacy. The target was a total of 10 cases, 7 cases in the active drug group, and 3 in the placebo group. The amount of change in upper extremity composite score (the sum of the average of the right and left HHD scores for grip, shoulder abductors, elbow flexors and elbow extensors) was used, and the secondary endpoints were the doctor's comprehensive evaluation and the GNE myopathy functional activity scale.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
14
The drug will be administered by the oral route with the same manner
The drug will be administered by the oral route with the same manner
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Osaka University Hospital
Suita, Osaka, Japan
National Center Hospital of Neurology and Psychiatry Hospita
Kodaira, Tokyo, Japan
Change from Baseline in the upper extremity composite score (the sum of the average of the right and left muscle strength measured by HHD (Hand held dynamometer) (kg) for grip, shoulder abductors, elbow flexors and elbow extensors)
Muscle strength based on the maximum voluntary isometric contraction (MVIC) is measured.
Time frame: Week 48
The effective rate in comprehensive judgement by the investigator
The investigator judges based on below 1 \~ 4 items. 1. The manual muscle testing (0 - 5) or grip strength (kg) 2. the upper extremity composite score (kg) 3. the change in the upper extremity composite score (kg) compared with the transition of non-active drug administered GNE myopathy patients 4. the other secondary endpoints
Time frame: Week 48
Change from Baseline in GNE Myopathy Functional Activity Scale (GNEM-FAS) upper extremity domain score
Upper extremity functional activity is assessed using the upper extremity domain sore of the GNEM-FAS instrument. It consists of 8 items (score 0-4 for each item), total domain score is 0 to 32 with higher scores representing greater activity.
Time frame: Week 48
Changes from Baseline in Individual muscle strength: Grip, shoulder abductors, elbow flexors, and elbow extensors comprising the upper extremity composite score (kg)
Muscle strength based on the maximum voluntary isometric contraction (MVIC) is measured.
Time frame: Week 48
Change from baseline in knee extensors muscle strength (kg)
Muscle strength based on the maximum voluntary isometric contraction (MVIC) is measured.
Time frame: Week 48
Change from Baseline in GNE Myopathy Functional Activity Scale (GNEM-FAS) mobility domain score
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Kumamoto University Hospital
Kumamoto, Japan
Mobility functional activity is assessed using the mobility domain sore of the GNEM-FAS instrument. It consists of 10 items (score 0-4 for each item), total domain score is 0 to 40 with higher scores representing greater activity.
Time frame: Week 48
Change from Baseline in GNE Myopathy Functional Activity Scale (GNEM-FAS) self-care domain score
Self-care functional activity is assessed using the self-care domain sore of the GNEM-FAS instrument. It consists of 7 items (score 0-4 for each item), total domain score is 0 to 28 with higher scores representing greater activity.
Time frame: Week 48